View analysts price targets for Silverback Therapeutics or view top-rated stocks among Wall Street analysts. This suggests a possible upside of 718.9 from the stocks current price. On average, they predict Silverback Therapeutics share price to reach 33.00 in the next twelve months. The firm’s 50 day moving average price is 3.25 and. Silverback Therapeutics Inc (NASDAQ:SBTX) has been in a tremendous tailspin the last two months. Their SBTX stock forecasts range from 5.00 to 52.00.

The firm has a market cap of 126.87 million, a PE ratio of -1.33 and a beta of 1.05. To learn more, visit View source version on businesswire. Silverback Therapeutics stock opened at 3.61 on Monday. Silverback Therapeutics is located in Seattle, Washington. Silverback’s platform enables the strategic pairing of proprietary payloads that modulate key disease modifying pathways with monoclonal antibodies directed at specific disease sites. is a biopharmaceutical company focused on leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered and tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. Members of the Silverback management team will also host investor meetings during the conference. Silverback Therapeutics ( NASDAQ:SBTX - Get Rating) last released its quarterly. The business has a 50-day moving average price of 3.36 and a 200 day moving average price of 4.36. Silverback Therapeutics has a twelve month low of 2.80 and a twelve month high of 35.63. The average rating score is and is based on 9 buy ratings, 2 hold ratings, and 0 sell ratings. 2 days ago &0183 &32 Shares of Silverback Therapeutics stock opened at 3.98 on Friday. The webcast of the presentation will be available on Silverback’s Investor Relations website for 30 days following the event. Silverback Therapeutics stock has received a consensus rating of buy. Laura Shawver, Ph.D., Silverback’s Chief Executive Officer, will provide a corporate overview on Tuesday, at 7:00 AM ET / 4:00 AM PT. Wainwright 24 th Global Investment Conference from May 23-25, 2022. (Nasdaq: SBTX) (“Silverback”), a biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases, today announced that Silverback management will participate in the H.C.

Silverback therapeutics stock